7,573.00

-1.50

-0.02%

51,961.00

-172.00

-0.33%

28,223.25

+95.75

+0.34%

Russell 2000 Futures

2,816.00

-1.80

-0.06%

4.8940

-0.0350

-0.71%

21.15

+1.73

+8.91%

3,946.60

-23.00

-0.58%

76,606.20

-1,891.47

-2.41%

Crude Oil Dec 26

96.63

+0.17

+0.18%

US Private Equity

10,836.30

-14.33

-0.13%

OTC Markets OTCID USD

AXIM Biotechnologies, Inc. (AXIM)

0.0033 +0.0003 (+10.00%)

At close: October 30 at 4:00:00 PM EDT

Loading Chart for AXIM

Chart Range Bar

Interval:

In partnership with ChartIQ

AXIM Biotechnologies Submits 510(k) to FDA for Next-Generation, Rapid Point-of-Care Tear Lactoferrin Test for Dry Eye Disease

AXIM Biotechnologies Submits 510(k) to FDA for Next-Generation, Rapid Point-of-Care Tear Lactoferrin Test for Dry Eye Disease

Exclusive: Axiom CEO on Hong Kong IPO plans, path to public markets

Exclusive: Axiom CEO on Hong Kong IPO plans, path to public markets

AXIM Biotechnologies, Inc. and Medical Marijuana, Inc. Enter Into Strategic Alliance to Research and Develop Applications and Uses of Patent for Water Soluble Cannabinoids

AXIM Biotechnologies, Inc. and Medical Marijuana, Inc. Enter Into Strategic Alliance to Research and Develop Applications and Uses of Patent for Water Soluble Cannabinoids

Medical Marijuana, Inc. and AXIM Biotechnologies, Inc. Enter Into Strategic Alliance to Research and Develop Applications and Uses of Patent for Water Soluble Cannabinoids

Medical Marijuana, Inc. and AXIM Biotechnologies, Inc. Enter Into Strategic Alliance to Research and Develop Applications and Uses of Patent for Water Soluble Cannabinoids

AXIM Biotechnologies Engages 624 Advisors, Owned and Managed by Dr. Alan J. Touch, Innovator and Global Regulatory Leader, as Chief Medical & Regulatory Affairs Advisor

AXIM Biotechnologies Engages 624 Advisors, Owned and Managed by Dr. Alan J. Touch, Innovator and Global Regulatory Leader, as Chief Medical & Regulatory Affairs Advisor

Mobilize your Website

View Site in Mobile | Classic

Share by: